James Ellis
Chief Scientific Officer Nocion Therapeutics
James has been CSO at Nocion since July 2018. He has over 25 years leadership experience in drug discovery in multiple therapeutic areas, working in organizations from biotech startups to large pharma. Most recently, James lead GSK’s Innovation Hub in Cambridge after serving as Vice President and Head of GSK’s Sirtuin Discovery Performance Unit. Prior to GSK, James was Vice President of Research for Surface Logix and the Executive Project Director and Chief Biology Advisor for NitroMed. Previously, James was the Group Director, Allergy and Respiratory Disease and Senior Director of Pharmacology at UCB Pharma where he was responsible for UCB’s global allergy and respiratory franchise research pipeline. Prior to joining industry, James was an Assistant Professor of Medicine at Johns Hopkins University, where he also did his post-doctoral research. James received his B.Sc. in Pharmacology from the University of Aberdeen in Scotland and his Ph.D. in Neurobiology from University College London
Seminars
- Selective targeting of sodium channels in nociceptors including NaV 1.7, NaV 1.8 and NaV 1.9
- Understand how this approach differs from conventional pain therapies and the benefits of mechanism-specific targeting
- Explore the potential for localized therapy that minimizes impact on mechanoreceptors and motor neurons
